Abstract
NADH/FAD fluorescence spectroscopy/imaging is an extremely useful tool to probe cellular metabolism and has been applied in the clinic such as early cancer detection. Recently, the potential of using NADH/FAD fluorescence as a biomarker to detect cell death has been investigated for development of cancer treatments with higher efficacy. This review aims to provide the updated information in cell death detection using the NADH/FAD fluorescence spectroscopy and imaging based on measurement of the intensity or lifetime of NADH or FAD fluorescence. The response of NADH fluorescence lifetime to metabolic perturbation, hypoxic environment, and anaerobic glycolysis (e.g., in precancerous tissues and stem cells) is also reviewed to discuss the nature and implications of the lifetime change of NADH fluorescence. Further studies are required to understand the actual site and mechanism of NADH binding of a specific death pathway for future successful in vivo detection of cell death using the NADH fluorescence lifetime.
Keywords: NAD(P)H and FAD fluorescence intensity and lifetime, redox ratio, mitochondrial respiration, cell death
Anti-Cancer Agents in Medicinal Chemistry
Title: Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Volume: 9 Issue: 9
Author(s): Hsing-Wen Wang, Yau-Huei Wei and Han-Wen Guo
Affiliation:
Keywords: NAD(P)H and FAD fluorescence intensity and lifetime, redox ratio, mitochondrial respiration, cell death
Abstract: NADH/FAD fluorescence spectroscopy/imaging is an extremely useful tool to probe cellular metabolism and has been applied in the clinic such as early cancer detection. Recently, the potential of using NADH/FAD fluorescence as a biomarker to detect cell death has been investigated for development of cancer treatments with higher efficacy. This review aims to provide the updated information in cell death detection using the NADH/FAD fluorescence spectroscopy and imaging based on measurement of the intensity or lifetime of NADH or FAD fluorescence. The response of NADH fluorescence lifetime to metabolic perturbation, hypoxic environment, and anaerobic glycolysis (e.g., in precancerous tissues and stem cells) is also reviewed to discuss the nature and implications of the lifetime change of NADH fluorescence. Further studies are required to understand the actual site and mechanism of NADH binding of a specific death pathway for future successful in vivo detection of cell death using the NADH fluorescence lifetime.
Export Options
About this article
Cite this article as:
Wang Hsing-Wen, Wei Yau-Huei and Guo Han-Wen, Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377718
DOI https://dx.doi.org/10.2174/187152009789377718 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Protein-Modified Magnetic Nanoparticles for Biomedical Applications
Current Organic Chemistry PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Cyclodextrins and their Derivatives as Carrier Molecules in Drug and Gene Delivery Systems
Current Organic Chemistry The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Microwave Assisted Synthesis, Biological Characterization and Docking Studies of Pyrimidine Derivatives
Current Microwave Chemistry Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism